The safety and efficacy of Naoxintong Capsules combined with Western medicine in treatment of chronic heart failure(CHF) were analyzed based on Meta-analysis system. Databases, such as CNKI, VIP, WanFang, PubMed, EMbase and Cochrane Library, were retrieved from the inception to 31 August, 2019, to collect literatures about the effect of Naoxintong Capsules in treating CHF. RevMan 5.3 software provided by Cochrane collaboration network was used for statistical processing of the extracted data. This study included 15 RCTs, involving 1 595 patients, including 802 cases in the treatment group and 787 cases in the control group. The quality of the literatures was generally low. Meta-analysis results showed that the clinical efficacy rate on patients can be significantly improved by adding Naoxintong Capsules to conventional Western medicine, so as to significantly increase chronic heart failure(RR=1.24, 95%CI[1.18, 1.31], P<0.000 01), ventricular ejection fraction(MD=3.96, 95%CI[2.64, 5.27], P<0.000 01), left ventricular short axis shortening rate(MD=4.17, 95%CI[2.25, 6.10], P<0.000 1), and stroke volume(MD=10.27, 95%CI[8.47, 12.08], P<0.000 01), and reduce type B natriuretic peptide(MD=-50.10, 95%CI[-68.42,-31.78], P<0.000 01), left ventricular end-diastolic diameter(MD=-5.69, 95%CI[-7.68,-3.69], P<0.000 01), left ventricular end-systolic diameter(MD=-4.05, 95%CI[-4.89,-3.21], P<0.000 01) and left ventricular end-systolic volume(MD=-6.67, 95%CI[-8.46,-4.88], P<0.000 01), with statistically significant differences. Naoxintong Capsules combined with Western medicine can improve the clinical efficacy on patients with chronic heart failure, and cardiac function indexes and B-type natriuretic peptide levels.
Keywords: Meta-analysis; Naoxintong Capsules; chronic heart failure; randomized controlled trial.